Tag: IMULDOSA
FDA approves Accord BioPharma’s biosimilar ‘IMULDOSA’ to treat chronic inflammatory conditions
Accord BioPharma (A division of Intas Pharmaceuticals) anticipates a commercial launch of IMULDOSA in the first half of 2025